Clinical Trial Update: Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease [Phase 2]

View source ↗

Summary

Phase 2 study of ISIS 681257 (AKCEA-APO(a)-LRx) in participants with elevated Lipoprotein(a) and cardiovascular disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Elevated Lipoprotein

Drugs mentioned

• AKCEA-APO(a)-LRx (ISIS 681257) (AKCEA-APO(a)-LRx)

Snippet

Sponsor: Akcea Therapeutics | Conditions: Elevated Lipoprotein(a), Cardiovascular Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-10-30